Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jeremy S. Abramson, Tanya Siddiqi, Leo I. Gordon, Matthew Alexander Lunning, Michael Wang, Jon E. Arnason, Amitkumar N. Mehta, Enkhee Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina M. Albertson, Jacob Garcia, Ana Kostic, Daniel Li, Yeonhee Kim, Maria Lia Palomba
Institutions: Massachusetts General Hospital, City Of Hope National Medical Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Nebraska Medical Center, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, University of Alabama at Birmingham, UAB Medicine, University of Colorado Anschutz, Fred Hutch Cancer Center, University of California, San Francisco, University of Pittsburgh Medical Center, Northside Hospital, Levine Cancer Institute, Bristol-Myers Squibb (United States), Juno Therapeutics (United States), Memorial Sloan Kettering Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3030085018